Beyond Air Sells 85% of NeuroNOS for Up to $32.5 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy XAIR?
Source: Benzinga
Beyond Air's stock price fell 8.14% as it crossed below the 5-day SMA amid mixed market conditions.
The company has entered into an agreement to sell 85% of its subsidiary NeuroNOS to XTL Biopharmaceuticals, which includes 19.9% of XTL's shares, $1 million in cash, and up to $32.5 million in milestone payments. This strategic move is aimed at enhancing Beyond Air's focus on its core operations while providing funding for NeuroNOS's development in autism and neuro-oncology treatments. The deal is expected to validate the scientific foundation of NeuroNOS and create significant value for shareholders.
This transaction positions Beyond Air to streamline its operations and potentially enhance shareholder value, despite the current stock decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XAIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XAIR
Wall Street analysts forecast XAIR stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.961
Low
6.00
Averages
6.00
High
6.00
Current: 0.961
Low
6.00
Averages
6.00
High
6.00
About XAIR
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Potential of High-Dose Inhaled Nitric Oxide for Antimicrobial Therapy
- Publication of Findings: Beyond Air has released an independent review article that comprehensively examines the efficacy of high-dose inhaled nitric oxide (iNO), highlighting its broad-spectrum antimicrobial potential in respiratory infections, which could transform existing treatment paradigms and drive innovation in the medical device sector.
- Compilation of Clinical Evidence: The article synthesizes data from 27 studies, demonstrating the safety and efficacy of high-dose iNO in various respiratory infections, including pneumonia and COVID-19, indicating strategic opportunities for the company in developing new therapies.
- Multimodal Mechanisms: High-dose iNO exhibits multiple mechanisms of action, including direct microbial killing, antiviral effects, and inflammation reduction, emphasizing its potential applications in hospital-acquired pneumonia and immunocompromised patients, potentially filling current treatment gaps.
- Future Research Directions: CEO Steve Lisi stated that the publication will serve as a catalyst for new scientific research, accelerating the clinical development of high-dose iNO and further solidifying the company's leadership position in the treatment of respiratory diseases.
See More
Beyond Air Reports Q3 Earnings with Revenue Beat
- Earnings Report: Beyond Air's Q3 earnings report reveals a GAAP EPS of -$0.85, missing expectations by $0.03, indicating ongoing challenges in profitability.
- Revenue Surge: The company reported revenues of $2.2M for the quarter, representing a substantial year-over-year increase of 105.6%, exceeding market expectations by $0.05M, highlighting strong product demand recovery.
- Executive Appointment: Beyond Air has appointed Dan Moorhead as CFO, aiming to enhance financial management and drive future strategic development for the company.
- Market Reaction: Despite the EPS miss, the significant revenue growth may bolster investor confidence in the company's future growth potential, particularly in the context of new product launches and market expansion efforts.
See More
Beyond Air Reports 105% Revenue Growth in Q3
- Significant Revenue Growth: Beyond Air reported a 105% year-over-year revenue increase to $2.2 million for fiscal Q3 2025, reflecting strong demand for its LungFit PH product in both U.S. and international markets, marking a crucial milestone in the company's commercialization journey.
- Strong Cash Position: As of December 31, 2025, the company reported approximately $22.3 million in cash and cash equivalents, bolstered by recent PIPE financing, which is expected to provide a runway into 2027, enhancing operational sustainability.
- Strategic Acquisition Plan: Beyond Air signed a binding letter of intent to acquire 85% of XTL Biopharmaceuticals, potentially receiving up to $32.5 million in cash and equity, further advancing its strategic positioning in neuro-oncology and autism treatment.
- Clinical Data Presentation: The company plans to present Phase 1a data from its UNO program at the AACR Annual Meeting in 2026, which is expected to increase market awareness of its innovative treatment solutions and support future commercialization efforts.
See More
Beyond Air to Announce Q3 Earnings on February 13
- Earnings Announcement Date: Beyond Air is set to announce its Q3 earnings on February 13 before market open, with a consensus EPS estimate of -$0.54, reflecting a significant 260% year-over-year decline, indicating serious challenges in profitability.
- Revenue Growth Expectations: Despite the poor EPS outlook, the revenue estimate stands at $2.15 million, representing a 100.9% year-over-year increase, which highlights the company's potential for sales growth and may provide support for future financial performance.
- Performance Forecast Revisions: Over the past year, Beyond Air has failed to beat EPS estimates 100% of the time and has only achieved a 25% beat rate on revenue estimates, indicating difficulties in managing market expectations effectively.
- Management Changes: Beyond Air has recently appointed Dan Moorhead as CFO and Duke Drewell as interim CFO, a leadership change that could impact the company's future financial strategy and execution capabilities.
See More
XTL Biopharmaceuticals Acquires 85% of NeuroNOS for $1M and Up to $32.5M in Milestones
- Acquisition Details: XTL will acquire 85% of NeuroNOS for 19.9% of its issued share capital, $1 million in cash, and contingent milestone payments up to $32.5 million, marking a strategic move into autism and neuro-oncology therapeutics.
- Positive Market Reaction: Following XTL's announcement to acquire NeuroNOS, shares of Beyond Air (XAIR) surged 149%, while XTLB shares rose 51% at the time of writing, indicating strong market approval of the deal.
- Autism Treatment Platform: NeuroNOS's drug development platform focuses on addressing the molecular mechanisms of autism, contrasting with existing treatments based on behavioral symptoms, which is expected to provide XTL with new therapeutic avenues in autism and neuro-oncology.
- Enhanced Policy Support: The U.S. government has allocated $50 million in NIH funding for autism research, reflecting a heightened focus on new drug development, which may provide XTL with policy backing and financial support for future growth.
See More
Beyond Air (XAIR) Sells 85% of NeuroNOS for Up to $32.5 Million
- Transaction Details: Beyond Air has entered into an agreement with XTL Biopharmaceuticals to sell 85% of its subsidiary NeuroNOS, which includes 19.9% of XTL's shares, $1 million in cash, and up to $32.5 million in milestone payments, indicating a strategic move in the biopharmaceutical sector.
- Market Potential: This deal positions XTL to become a key player in the rapidly growing autism therapeutics market, addressing critical global healthcare needs, particularly for underserved patient populations, thus holding significant social value and commercial prospects.
- R&D Support: NeuroNOS focuses on autism and neuro-oncology treatments and holds FDA Orphan Drug Designations, providing market exclusivity and accelerated approval pathways, which are expected to yield up to $5.5 million in clinical development payments for Beyond Air, facilitating its R&D progress.
- Shareholder Value Enhancement: Beyond Air's CEO Steve Lisi stated that this transaction validates the scientific foundation of NeuroNOS and creates significant value for shareholders, as it is expected to drive the advancement of NeuroNOS's pipeline with dedicated resources and funding.
See More
Potential of High-Dose Inhaled Nitric Oxide for Antimicrobial Therapy
- Publication of Findings: Beyond Air has released an independent review article that comprehensively examines the efficacy of high-dose inhaled nitric oxide (iNO), highlighting its broad-spectrum antimicrobial potential in respiratory infections, which could transform existing treatment paradigms and drive innovation in the medical device sector.
- Compilation of Clinical Evidence: The article synthesizes data from 27 studies, demonstrating the safety and efficacy of high-dose iNO in various respiratory infections, including pneumonia and COVID-19, indicating strategic opportunities for the company in developing new therapies.
- Multimodal Mechanisms: High-dose iNO exhibits multiple mechanisms of action, including direct microbial killing, antiviral effects, and inflammation reduction, emphasizing its potential applications in hospital-acquired pneumonia and immunocompromised patients, potentially filling current treatment gaps.
- Future Research Directions: CEO Steve Lisi stated that the publication will serve as a catalyst for new scientific research, accelerating the clinical development of high-dose iNO and further solidifying the company's leadership position in the treatment of respiratory diseases.
See More
Beyond Air Reports Q3 Earnings with Revenue Beat
- Earnings Report: Beyond Air's Q3 earnings report reveals a GAAP EPS of -$0.85, missing expectations by $0.03, indicating ongoing challenges in profitability.
- Revenue Surge: The company reported revenues of $2.2M for the quarter, representing a substantial year-over-year increase of 105.6%, exceeding market expectations by $0.05M, highlighting strong product demand recovery.
- Executive Appointment: Beyond Air has appointed Dan Moorhead as CFO, aiming to enhance financial management and drive future strategic development for the company.
- Market Reaction: Despite the EPS miss, the significant revenue growth may bolster investor confidence in the company's future growth potential, particularly in the context of new product launches and market expansion efforts.
See More
Beyond Air Reports 105% Revenue Growth in Q3
- Significant Revenue Growth: Beyond Air reported a 105% year-over-year revenue increase to $2.2 million for fiscal Q3 2025, reflecting strong demand for its LungFit PH product in both U.S. and international markets, marking a crucial milestone in the company's commercialization journey.
- Strong Cash Position: As of December 31, 2025, the company reported approximately $22.3 million in cash and cash equivalents, bolstered by recent PIPE financing, which is expected to provide a runway into 2027, enhancing operational sustainability.
- Strategic Acquisition Plan: Beyond Air signed a binding letter of intent to acquire 85% of XTL Biopharmaceuticals, potentially receiving up to $32.5 million in cash and equity, further advancing its strategic positioning in neuro-oncology and autism treatment.
- Clinical Data Presentation: The company plans to present Phase 1a data from its UNO program at the AACR Annual Meeting in 2026, which is expected to increase market awareness of its innovative treatment solutions and support future commercialization efforts.
See More
Beyond Air to Announce Q3 Earnings on February 13
- Earnings Announcement Date: Beyond Air is set to announce its Q3 earnings on February 13 before market open, with a consensus EPS estimate of -$0.54, reflecting a significant 260% year-over-year decline, indicating serious challenges in profitability.
- Revenue Growth Expectations: Despite the poor EPS outlook, the revenue estimate stands at $2.15 million, representing a 100.9% year-over-year increase, which highlights the company's potential for sales growth and may provide support for future financial performance.
- Performance Forecast Revisions: Over the past year, Beyond Air has failed to beat EPS estimates 100% of the time and has only achieved a 25% beat rate on revenue estimates, indicating difficulties in managing market expectations effectively.
- Management Changes: Beyond Air has recently appointed Dan Moorhead as CFO and Duke Drewell as interim CFO, a leadership change that could impact the company's future financial strategy and execution capabilities.
See More
XTL Biopharmaceuticals Acquires 85% of NeuroNOS for $1M and Up to $32.5M in Milestones
- Acquisition Details: XTL will acquire 85% of NeuroNOS for 19.9% of its issued share capital, $1 million in cash, and contingent milestone payments up to $32.5 million, marking a strategic move into autism and neuro-oncology therapeutics.
- Positive Market Reaction: Following XTL's announcement to acquire NeuroNOS, shares of Beyond Air (XAIR) surged 149%, while XTLB shares rose 51% at the time of writing, indicating strong market approval of the deal.
- Autism Treatment Platform: NeuroNOS's drug development platform focuses on addressing the molecular mechanisms of autism, contrasting with existing treatments based on behavioral symptoms, which is expected to provide XTL with new therapeutic avenues in autism and neuro-oncology.
- Enhanced Policy Support: The U.S. government has allocated $50 million in NIH funding for autism research, reflecting a heightened focus on new drug development, which may provide XTL with policy backing and financial support for future growth.
See More
Beyond Air (XAIR) Sells 85% of NeuroNOS for Up to $32.5 Million
- Transaction Details: Beyond Air has entered into an agreement with XTL Biopharmaceuticals to sell 85% of its subsidiary NeuroNOS, which includes 19.9% of XTL's shares, $1 million in cash, and up to $32.5 million in milestone payments, indicating a strategic move in the biopharmaceutical sector.
- Market Potential: This deal positions XTL to become a key player in the rapidly growing autism therapeutics market, addressing critical global healthcare needs, particularly for underserved patient populations, thus holding significant social value and commercial prospects.
- R&D Support: NeuroNOS focuses on autism and neuro-oncology treatments and holds FDA Orphan Drug Designations, providing market exclusivity and accelerated approval pathways, which are expected to yield up to $5.5 million in clinical development payments for Beyond Air, facilitating its R&D progress.
- Shareholder Value Enhancement: Beyond Air's CEO Steve Lisi stated that this transaction validates the scientific foundation of NeuroNOS and creates significant value for shareholders, as it is expected to drive the advancement of NeuroNOS's pipeline with dedicated resources and funding.
See More
